tiprankstipranks
Trending News
More News >
Bolt Biotherapeutics (BOLT)
NASDAQ:BOLT
Advertisement

Bolt Biotherapeutics (BOLT) AI Stock Analysis

Compare
225 Followers

Top Page

BOLT

Bolt Biotherapeutics

(NASDAQ:BOLT)

Rating:52Neutral
Price Target:
$7.00
▲(4.32%Upside)
Bolt Biotherapeutics' overall score of 52 reflects its financial struggles, particularly its significant net losses, which weigh heavily on valuation. Technical indicators show mixed signals, with short-term positive momentum but longer-term bearish trends. The absence of earnings call data and corporate events means these factors do not influence the score.
Positive Factors
Clinical Performance
Bolt Biotherapeutics plans to report preliminary Phase 1 data for their lead program targeting Claudin 18.2 in gastric and gastroesophageal cancers, which could demonstrate clinical activity and competitiveness.
Safety Profile
BDC-4182, Bolt's lead program, was tolerated at the highest dose tested in non-human primates, indicating a favorable safety profile.
Negative Factors
Competitive Landscape
Several peer companies have ongoing or discontinued programs targeting CLDN18.2, indicating a competitive landscape for Bolt Biotherapeutics.
Financial Performance
Bolt reported 4Q24 revenue of $0.0M and EPS of ($0.42), compared to estimates of $0.9M and ($0.34), respectively.

Bolt Biotherapeutics (BOLT) vs. SPDR S&P 500 ETF (SPY)

Bolt Biotherapeutics Business Overview & Revenue Model

Company DescriptionBolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
How the Company Makes MoneyBolt Biotherapeutics makes money primarily through the development and commercialization of its proprietary immune-oncology therapies. The company generates revenue through strategic partnerships, collaborations, and licensing agreements with larger pharmaceutical companies that provide funding for research and development in exchange for rights to commercialize successful therapies. Additionally, Bolt Biotherapeutics may receive milestone payments and royalties from these partners based on the achievement of certain clinical, regulatory, and sales milestones. The company's financial sustainability is highly dependent on the successful advancement of its clinical pipeline and its ability to establish and maintain strategic alliances in the competitive biotechnology space.

Bolt Biotherapeutics Financial Statement Overview

Summary
Bolt Biotherapeutics is experiencing ongoing losses with a slight revenue growth. The balance sheet reflects low debt and a stable equity position, but cash flow inefficiencies persist, affecting overall financial health.
Income Statement
45
Neutral
Bolt Biotherapeutics shows a modest revenue growth with a 34.3% increase from 2022 to 2023 and a slight decline of 2.4% from 2023 to 2024. However, the company has been experiencing significant losses with a negative net profit margin of -820.7% in 2024. The gross profit margin is stable at 100% for 2024, indicating that cost of goods sold is negligible compared to revenue, but high operational expenses continue to weigh down profitability.
Balance Sheet
55
Neutral
The company maintains a relatively low debt-to-equity ratio of 0.44 in 2024, suggesting a conservative leverage approach. However, return on equity remains negative due to consistent losses, indicating inefficiencies in generating returns for shareholders. The equity ratio stands at 57.4%, reflecting a stable financial structure with more than half of its assets funded by equity.
Cash Flow
50
Neutral
Operating cash flow remains negative, but improved slightly from -69.5 million in 2023 to -61.3 million in 2024. Free cash flow also increased marginally to -61.3 million, indicating ongoing challenges in cash generation. The operating cash flow to net income ratio of 0.97 suggests that cash flow is closely aligned with net losses, while free cash flow to net income ratio mirrors this trend.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue7.69M7.88M5.73M1.26M231.00K
Gross Profit5.51M5.99M838.00K-2.41M-40.13M
EBITDA-66.45M-74.34M-88.66M-91.59M-48.57M
Net Income-63.12M-69.20M-85.88M-104.39M-72.27M
Balance Sheet
Total Assets99.63M159.78M227.81M307.72M46.54M
Cash, Cash Equivalents and Short-Term Investments47.32M102.19M168.89M186.22M22.84M
Total Debt25.21M20.22M22.61M24.36M10.88M
Total Liabilities42.43M47.04M56.30M57.60M151.49M
Stockholders Equity57.20M112.74M171.51M250.12M-104.95M
Cash Flow
Free Cash Flow-61.33M-69.73M-78.46M-59.40M-50.57M
Operating Cash Flow-61.29M-69.53M-76.50M-57.07M-47.31M
Investing Cash Flow57.58M71.04M57.86M-232.20M-20.59M
Financing Cash Flow108.00K253.00K503.00K311.11M39.60M

Bolt Biotherapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price6.71
Price Trends
50DMA
6.12
Positive
100DMA
6.94
Negative
200DMA
9.15
Negative
Market Momentum
MACD
-0.02
Negative
RSI
62.92
Neutral
STOCH
55.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLT, the sentiment is Positive. The current price of 6.71 is above the 20-day moving average (MA) of 5.91, above the 50-day MA of 6.12, and below the 200-day MA of 9.15, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 62.92 is Neutral, neither overbought nor oversold. The STOCH value of 55.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BOLT.

Bolt Biotherapeutics Risk Analysis

Bolt Biotherapeutics disclosed 64 risk factors in its most recent earnings report. Bolt Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Bolt Biotherapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.61B0.04-62.94%2.44%16.14%0.33%
52
Neutral
$12.86M-83.92%-67.87%0.40%
48
Neutral
$12.76M-117.16%175.03%55.34%
41
Neutral
$41.31M-89.73%-100.00%-292.59%
39
Underperform
$21.84M-2951.24%14.17%28.26%
34
Underperform
$14.96M-208.72%56.38%
34
Underperform
$8.16M-174.66%38.53%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BOLT
Bolt Biotherapeutics
6.71
-8.29
-55.27%
CRIS
Curis
1.82
-4.30
-70.26%
MEIP
MEI Pharma
6.20
2.64
74.16%
CLRB
Cellectar Biosciences
5.59
-63.11
-91.86%
BRTX
BioRestorative Therapies
1.70
0.08
4.94%
INAB
IN8bio
2.46
-22.71
-90.23%

Bolt Biotherapeutics Corporate Events

Stock Split
Bolt Biotherapeutics Announces Reverse Stock Split
Neutral
Jun 6, 2025

On June 6, 2025, Bolt Biotherapeutics implemented a one-for-twenty reverse stock split of its common stock, following approval from stockholders and the Board of Directors on May 27, 2025. This move affects the company’s outstanding shares, equity incentive plans, and stock options, with trading on a split-adjusted basis set to begin on June 9, 2025, on the Nasdaq Capital Market under the ticker ‘BOLT’.

The most recent analyst rating on (BOLT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Bolt Biotherapeutics stock, see the BOLT Stock Forecast page.

Delistings and Listing ChangesStock Split
Bolt Biotherapeutics Announces Reverse Stock Split Approval
Neutral
Jun 4, 2025

On May 27, 2025, Bolt Biotherapeutics‘ Board of Directors approved a one-for-twenty reverse stock split, effective June 6, 2025. This move, intended to consolidate shares and adjust the exercise price of stock options, will see the company’s stock begin trading on a split-adjusted basis on June 9, 2025, under the ticker ‘BOLT’.

The most recent analyst rating on (BOLT) stock is a Hold with a $1.25 price target. To see the full list of analyst forecasts on Bolt Biotherapeutics stock, see the BOLT Stock Forecast page.

Executive/Board ChangesShareholder MeetingsStock Split
Bolt Biotherapeutics Approves Key Governance Changes
Neutral
May 28, 2025

On May 27, 2025, Bolt Biotherapeutics held its annual meeting of stockholders, where key decisions were made regarding the company’s governance and financial strategies. During the meeting, two directors were elected to the board, the selection of PricewaterhouseCoopers LLP as the independent auditor for 2025 was ratified, and an amendment for a reverse stock split was approved. These decisions are expected to influence the company’s operational strategies and financial structuring, potentially impacting shareholder value and market perception.

The most recent analyst rating on (BOLT) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Bolt Biotherapeutics stock, see the BOLT Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025